4D Molecular Therapeutics Income Statement (2019-2025) | FDMT

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
2.00M14.58M1.37M0.09M1.22M0.16M0.50M1.25M0.30M0.24M20.20M-0.02M0.03M0.01M0.00M0.00M0.01M0.01M0.09M85.09M
Operating items
Research & Development (Quarter)
12.77M15.22M15.84M17.53M19.38M20.42M18.94M21.50M22.41M23.58M25.07M26.03M27.87M31.86M38.48M43.09M40.70M47.95M49.44M57.61M
Selling, General & Administrative (Quarter)
5.54M6.95M8.19M7.33M8.23M8.17M8.05M8.47M7.99M8.79M9.11M10.61M10.29M10.60M12.65M13.03M12.94M11.52M11.84M12.77M
Operating Expenses (Quarter)
18.31M22.18M24.03M24.86M27.61M28.59M27.00M29.97M30.40M32.38M34.18M36.63M38.16M42.46M51.13M56.12M53.63M59.47M61.27M70.38M
Operating Income (Quarter)
-16.31M-7.60M-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M
EBIT (Quarter)
-16.31M-7.60M-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.43M-0.31M0.10M0.34M0.80M1.34M1.44M2.51M3.88M4.38M5.75M7.55M7.29M6.47M5.58M4.86M4.33M4.70M
Other Non Operating Income (Quarter)
-0.10M-0.01M-0.01M-0.05M0.01M0.00M-0.02M0.01M-0.16M-0.01M-0.01M-0.04M-0.00M-0.02M0.07M-0.06M-0.02M-0.02M
Non Operating Income (Quarter)
-0.10M0.01M0.42M-0.32M-0.05M0.01M-1.23M-0.02M0.01M-0.16M4.37M-0.01M7.50M7.29M6.45M0.07M-0.06M-0.02M19.45M
Net income details
EBT (Quarter)
-16.30M-7.59M-22.23M-25.08M-26.29M-28.09M-25.70M-27.38M-28.66M-29.62M-10.10M-32.27M-32.39M-34.91M-43.84M-49.65M-48.04M-54.60M-56.85M19.42M
Profit After Tax (Quarter)
-16.41M-7.59M-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M
Income from Continuing Operations (Quarter)
-16.30M-7.59M-22.23M-25.08M-26.29M-28.09M-25.70M-27.38M-28.66M-29.62M-10.10M-32.27M-32.39M-34.91M-43.84M-49.65M-48.04M-54.60M-56.85M19.42M
Consolidated Net Income (Quarter)
-16.30M-7.59M-22.23M-25.08M-26.29M-28.09M-25.70M-27.38M-28.66M-29.62M-10.10M-32.27M-32.39M-34.91M-43.84M-49.65M-48.04M-54.60M-56.85M19.42M
Income towards Parent Company (Quarter)
-16.30M-7.59M-22.23M-25.08M-26.29M-28.09M-25.70M-27.38M-28.66M-29.62M-10.10M-32.27M-32.39M-34.91M-43.84M-49.65M-48.04M-54.60M-56.85M19.42M
Net Income towards Common Stockholders (Quarter)
-16.41M-7.59M-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M
Additional items
EPS (Basic) (Quarter)
-0.61-0.28-0.82-0.85-0.82-0.87-0.79-0.84-0.88-0.77-0.24-0.77-0.66-0.63-0.79-0.90-0.86-0.98-1.010.43
EPS (Weighted Average and Diluted) (Quarter)
-0.28-0.82-0.85-0.82-0.87-0.79-0.84-0.88-0.77-0.24-0.77-0.66-0.63-0.79-0.90-0.86-0.98-1.010.43
Shares Outstanding (Weighted Average) (Quarter)
26.69M26.74M27.02M27.73M32.23M32.26M32.39M32.35M32.72M38.34M42.26M39.13M49.27M55.28M55.55M53.94M55.74M55.84M56.13M57.93M
Shares Outstanding (Diluted Average) (Quarter)
26.72M26.82M27.73M32.23M32.32M32.39M32.35M32.72M38.34M42.26M39.13M49.27M52.28M55.55M53.94M55.74M55.84M55.93M57.93M
EBITDA (Quarter)
-16.31M-7.60M-22.66M-24.76M-26.39M-28.43M-26.50M-28.72M-30.11M-32.14M-13.97M-36.65M-38.14M-42.46M-51.13M-56.12M-53.62M-59.46M-61.19M14.71M
Shares Outstanding (Quarter)
26.69M26.89M27.17M32.22M32.26M32.38M32.39M32.63M33.24M42.02M42.75M43.08M51.16M51.91M52.00M45.79M46.32M46.70M46.77M57.61M